If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Pfizer To Purchase ADHD Drug Maker NextWave

Acquisition will be an up to $700 million entry into the ADHD market

by Rick Mullin
October 26, 2012 | A version of this story appeared in Volume 90, Issue 44

Pfizer plans to acquire NextWave Pharmaceuticals, a specialty drug company focused on attention-deficit hyperactivity disorder (ADHD) and other central nervous system disorders. NextWave’s Quillivant XR, an extended-release version of the generic ADHD drug methylphenidate, won FDA approval in September.

Pfizer put up $20 million earlier this year for an option to acquire NextWave, and it will pay $255 million more upon the close of the deal, which is expected by the end of the year. Additional milestone payments could bring the value of the acquisition to nearly $700 million.

The purchase illustrates a shift in strategy for a major drug company that in recent years has made multi-billion-dollar acquisitions of other big drugmakers. Pfizer historically eschewed generics. But after the loss of patent protection for its cholesterol drug Lipitor, the biggest-selling drug in history, and the downsizing of its in-house R&D organization, Pfi­zer is signaling an intention to increase its presence in generics.

The deal also marks Pfizer’s entry into the competitive ADHD market, with the first once-daily liquid formulation of methylphenidate. The drug was discovered by Ciba, now Novartis, in the 1940s and first marketed as Ritalin. “This agreement demonstrates our focused expansion of the established-products, U.S. brands business,” says Albert Bourla, president of Pfizer’s established-products unit.

Two patents on Quillivant XR’s extended-release technology are held by Tris Pharma, which developed the drug in partnership with NextWave. NextWave holds exclusive North American marketing rights to the drug.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.